# ACF Immune Gene Expression Analysis - Complete Reconstruction & Publication

## PROJECT STATUS: 85% COMPLETE - FINAL PUSH TO PUBLICATION

**Last Updated:** October 19, 2025  
**Target Submission:** 4-6 weeks  
**Recommended Journal:** Clinical Cancer Research or Cancer Research

---

## PHASE 1: COMPREHENSIVE UNDERSTANDING & ANALYSIS ✅ COMPLETE

### 1.1 Manuscript Deep Dive Analysis ✅
- [x] Extract and analyze manuscript structure (8,413 words, 8 sections)
- [x] Identify main findings (PD1, chemokines, immune signatures)
- [x] Document all figures (5 main + supplementary)
- [x] List all tables (Table 1 demographics, Table 2 chemokines)
- [x] Identify gaps (Discussion needs revision, some figures need remake)
- [x] Assess journal readiness (85% complete, target CCR or Cancer Research)

### 1.2 Data Inventory & Understanding ✅
- [x] Catalog all data files (expression matrices, DGE, PCA, metadata)
- [x] Analyze key data files (395 genes, 40 samples, 10 patients)
- [x] Create comprehensive data dictionary (see COMPREHENSIVE_PROJECT_ANALYSIS.md)
- [x] Document data relationships (epithelial/stromal, ACF/normal)
- [x] Verify data integrity (all files present and loadable)

### 1.3 Analysis Pipeline Reconstruction ✅
- [x] Document Bo's complete workflow (10-step pipeline)
- [x] Identify statistical methods (DESeq2, VST, Wald test, FDR)
- [x] Extract key results (113 epi DEGs, 93 stro DEGs)
- [x] Document software versions (R 3.6.3, DESeq2 1.26.0)
- [x] Create workflow diagram (in comprehensive report)

### 1.4 GitHub Repository Setup ⏳
- [ ] Clone ACF-Immune-Analysis repository
- [ ] Set up directory structure (data/, scripts/, figures/, docs/)
- [ ] Create comprehensive README.md
- [ ] Upload COMPREHENSIVE_PROJECT_ANALYSIS.md
- [ ] Initialize .gitignore for R/Python projects

---

## PHASE 2: REPRODUCIBLE ANALYSIS SCRIPTS 📊 IN PROGRESS

### 2.1 Master Analysis Script Development ⏳
- [ ] Create ACF_master_analysis.R with complete pipeline
- [ ] Section 1: Setup and data loading
- [ ] Section 2: Quality control and filtering
- [ ] Section 3: DESeq2 differential expression (separate epi/stro)
- [ ] Section 4: PCA analysis (pooled and separate)
- [ ] Section 5: Pathway enrichment (clusterProfiler/enrichR)
- [ ] Section 6: Gene correlation networks
- [ ] Section 7: Immune cell deconvolution (immunedeconv)
- [ ] Section 8: Figure generation (all manuscript figures)
- [ ] Section 9: JMP data export
- [ ] Section 10: Summary report generation

### 2.2 Figure Generation Scripts ⏳
- [ ] Figure 1: Study design schematic + ACF histology
- [ ] Figure 2: PCA plots (A: all samples, B: epi/stro split, C-D: separate)
- [ ] Figure 3: Volcano plots + heatmaps (NEEDS REMAKE with new DGE)
- [ ] Figure 4: GSEA pathway enrichment bar charts (NEEDS REMAKE)
- [ ] Figure 5: PD1/CD8 immunofluorescence (EXISTS, may enhance)
- [ ] Supplementary Figure S1: Additional PCA views
- [ ] Supplementary Figure S2: Gene expression patterns
- [ ] Supplementary Figure S3: Pathway networks
- [ ] Supplementary Figure S4: Correlation heatmaps

### 2.3 Additional Analysis Scripts
- [ ] Gene-gene correlation analysis (mentioned in manuscript)
- [ ] Immune cell type deconvolution (CIBERSORT/quanTIseq)
- [ ] Pathway network visualization (Cytoscape/igraph)
- [ ] Clinical correlation analysis (age, BMI, polyps, ACF count)
- [ ] Comparison with TCGA CRC data (if time permits)

---

## PHASE 3: MANUSCRIPT COMPLETION 📝 PRIORITY

### 3.1 Critical Revisions Needed
- [ ] **DISCUSSION SECTION** - Major rewrite needed (currently 2,124 words)
  - [ ] Reorganize into clear subsections
  - [ ] Focus on main findings (PD1, chemokines)
  - [ ] Strengthen clinical implications
  - [ ] Better literature integration
  - [ ] Add mechanistic model figure
  - [ ] Conclude with risk stratification potential

- [ ] **METHODS SECTION** - Clarifications needed
  - [ ] Explain two-replicate strategy clearly
  - [ ] Specify exact DESeq2 parameters
  - [ ] Justify separate epi/stro analysis
  - [ ] Add more detail on normalization
  - [ ] Clarify gene filtering criteria

- [ ] **RESULTS SECTION** - Minor fixes
  - [ ] Fix PD1 terminology (up vs down confusion)
  - [ ] Justify genes with p>0.05 (CXCL9, PECAM1)
  - [ ] Add more quantification details
  - [ ] Better integration of epi-stro findings

### 3.2 Tables to Create/Revise
- [ ] Table 1: Demographics (move to supplementary?)
- [ ] Table 2: Chemokine genes (REMAKE as proper table, not screenshot)
- [ ] Table S1: Complete DGE results (epithelial)
- [ ] Table S2: Complete DGE results (stromal)
- [ ] Table S3: GSEA pathway enrichment summary
- [ ] Table S4: Gene panel categories
- [ ] Table S5: Sample sequencing metrics

### 3.3 Figure Legends
- [ ] Write detailed legend for Figure 1
- [ ] Write detailed legend for Figure 2
- [ ] Write detailed legend for Figure 3
- [ ] Write detailed legend for Figure 4
- [ ] Write detailed legend for Figure 5
- [ ] Write legends for all supplementary figures

---

## PHASE 4: GITHUB REPOSITORY & DELIVERABLES 📦

### 4.1 Repository Organization
- [ ] Create directory structure
- [ ] Upload all analysis scripts
- [ ] Add processed data files
- [ ] Create comprehensive README
- [ ] Add analysis documentation
- [ ] Include figure generation code

### 4.2 Documentation Files
- [ ] README.md (project overview, quick start)
- [ ] DATA_DICTIONARY.md (all variables explained)
- [ ] ANALYSIS_GUIDE.md (step-by-step instructions)
- [ ] REPRODUCIBILITY_GUIDE.md (how to reproduce all results)
- [ ] CHANGELOG.md (version history)

### 4.3 JMP Data Export for Dr. Nelson
- [ ] Expression matrix (normalized, all samples)
- [ ] Expression matrix (epithelial only)
- [ ] Expression matrix (stromal only)
- [ ] DGE results (epithelial ACF vs Normal)
- [ ] DGE results (stromal ACF vs Normal)
- [ ] PCA coordinates (all analyses)
- [ ] Sample metadata (patient info, conditions)
- [ ] Gene annotations (categories, functions)
- [ ] JMP workbook with all data integrated
- [ ] Analysis guide for Dr. Nelson

---

## PHASE 5: SUBMISSION PREPARATION 🎯

### 5.1 Manuscript Finalization
- [ ] Incorporate all revisions
- [ ] Professional editing (grammar, style)
- [ ] Format for target journal (CCR or Cancer Research)
- [ ] Check word limits and figure limits
- [ ] Verify all references are formatted correctly
- [ ] Create graphical abstract
- [ ] Write highlights (3-5 bullet points)

### 5.2 Submission Package
- [ ] Cover letter (emphasize novelty and impact)
- [ ] Manuscript (Word format)
- [ ] All figures (high-res TIFF/PDF)
- [ ] All tables (Word/Excel)
- [ ] Supplementary materials
- [ ] Author contributions statement
- [ ] Conflict of interest statement
- [ ] Funding acknowledgments
- [ ] Data availability statement

### 5.3 Data Deposition (if required)
- [ ] GEO submission (raw sequencing data)
- [ ] GitHub repository (analysis code)
- [ ] Supplementary data files
- [ ] README for data access

---

## IMMEDIATE PRIORITIES (THIS WEEK)

### Priority 1: Master Analysis Script ⭐⭐⭐
- [ ] Create ACF_master_analysis.R
- [ ] Test on all data files
- [ ] Generate all figures
- [ ] Export JMP data
- [ ] Document thoroughly

### Priority 2: GitHub Repository Setup ⭐⭐⭐
- [ ] Clone repository
- [ ] Set up directory structure
- [ ] Upload comprehensive analysis report
- [ ] Create README
- [ ] Push initial commit

### Priority 3: Figure Remake ⭐⭐
- [ ] Figure 3: Volcano plots + heatmaps
- [ ] Figure 4: GSEA bar charts
- [ ] Ensure publication quality

### Priority 4: Discussion Rewrite ⭐⭐
- [ ] Outline new structure
- [ ] Draft main sections
- [ ] Integrate feedback from comprehensive analysis

---

## SUCCESS METRICS

- [x] **Understanding:** Complete grasp of project, data, and analysis (100%)
- [ ] **Reproducibility:** Can run entire analysis from scratch (0%)
- [ ] **Figures:** All publication-ready (40%)
- [ ] **Manuscript:** Ready for submission (85%)
- [ ] **Documentation:** Complete and clear (60%)
- [ ] **Repository:** Organized and accessible (0%)

---

## NOTES & DECISIONS

**Key Decisions Made:**
1. Target journal: Clinical Cancer Research or Cancer Research
2. Timeline: 4-6 weeks to submission
3. Focus: Complete analysis scripts first, then manuscript revision
4. Priority: Reproducibility and documentation

**Outstanding Questions:**
1. What are the two technical replicates? (same LCM or different extractions?)
2. Why are some samples labeled "3E" or "3S"?
3. Should Table 1 (demographics) be in main text or supplementary?
4. Do we have any follow-up data on these patients?

**Next Review Point:** After master script completion